Extending Treatment Durability With Next-Generation Neovascular AMD Therapies

ReachMD CME

CME credits: 0.50
Valid until: 25-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.